Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Early trial tests Double-Punch therapy for stubborn blood cancer

NCT ID NCT05338775

Summary

This early-stage study is testing the safety of combining two different types of immunotherapy drugs for people with multiple myeloma that has returned or stopped responding to other treatments. The main goal is to find safe dose levels and understand side effects when these drugs are used together. It involves 74 participants whose cancer is no longer responding to standard therapies.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • CHU Poitiers - Hopital la Miletrie

    Poitiers, 86021, France

  • CHU de Montpellier Hopital Saint Eloi

    Montpellier, 34295, France

  • CHU de Nantes hotel Dieu

    Nantes, 44093, France

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Colorado Blood Cancer Institute

    Denver, Colorado, 80218, United States

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, 08916, Spain

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

  • Institut Universitaire du Cancer Toulouse Oncopole

    Toulouse, 31059, France

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Sarah Cannon Research Institute

    Nashville, Tennessee, 37203, United States

  • The Blavatnik Family Chelsea Medical Center at Mount Sinai

    New York, New York, 10011, United States

  • Universitaetsklinikum Hamburg Eppendorf

    Hamburg, 20246, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, 69120, Germany

  • Universitatsklinikum Carl Gustav Carus Dresden

    Dresden, 01307, Germany

  • Universitatsklinikum Wurzburg

    Würzburg, 97080, Germany

  • Vanderbilt Ingram Cancer Center

    Nashville, Tennessee, 37232, United States

  • Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina, 27157, United States

Conditions

Explore the condition pages connected to this study.